Francesco Blasi
A5004487731- Cystic Fibrosis Research Advances
- Pneumonia and Respiratory Infections
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory viral infections research
- Asthma and respiratory diseases
- Respiratory and Cough-Related Research
- Pediatric health and respiratory diseases
- Neonatal Respiratory Health Research
- Tracheal and airway disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- Respiratory Support and Mechanisms
- Nosocomial Infections in ICU
- Tuberculosis Research and Epidemiology
- COVID-19 Clinical Research Studies
- Reproductive tract infections research
- Inhalation and Respiratory Drug Delivery
- Transplantation: Methods and Outcomes
- Mycobacterium research and diagnosis
- Antibiotic Resistance in Bacteria
- Emergency and Acute Care Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Long-Term Effects of COVID-19
- Delphi Technique in Research
- SARS-CoV-2 and COVID-19 Research
- Antibiotic Use and Resistance
University of Milan
2016-2025
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2006-2024
Ospedale Maggiore
2013-2024
Cystic Fibrosis Foundation
2024
Cystic Fibrosis Research Foundation
2020-2024
Light Prescriptions Innovators (Spain)
2024
Vlaamse Vereniging voor Obstetrie en Gynaecolo
2024
COPE Galway
2024
Ninewells Hospital
2017-2024
There is considerable variation in disease behavior among patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes 2019 (Covid-19). Genomewide association analysis may allow for identification of potential genetic factors involved development Covid-19.
Bronchiectasis in adults is a chronic disorder associated with poor quality of life and frequent exacerbations many patients. There have been no previous international guidelines.The European Respiratory Society guidelines for the management adult bronchiectasis describe appropriate investigation treatment strategies determined by systematic review literature.A multidisciplinary group representing respiratory medicine, microbiology, physiotherapy, thoracic surgery, primary care, methodology...
We hypothesize that hydrocortisone infusion in severe community-acquired pneumonia attenuates systemic inflammation and leads to earlier resolution of a reduction sepsis-related complications. In multicenter trial, patients admitted the Intensive Care Unit (ICU) with received protocol-guided antibiotic treatment were randomly assigned or placebo. Hydrocortisone was given as an intravenous 200-mg bolus followed by at rate 10 mg/hour for 7 days. Primary end-points study improvement PaO2:FIO2...
There is a need for clear definition of exacerbations used in clinical trials patients with bronchiectasis. An expert conference was convened to develop consensus an exacerbation use research.A systematic review definitions from January 2000 until December 2015 and involving adults bronchiectasis conducted. A Delphi process followed by round-table meeting experts organised reach definition. These came Europe (representing the European Multicentre Bronchiectasis Research Collaboration), North...
Median survival has increased in people with cystic fibrosis (CF) during the past six decades, which led to an number of adults CF. The future impact changes CF demographics not been evaluated. aim this study was estimate children and 34 European countries by 2025. Data were obtained from Cystic Fibrosis Society Patient Registry. Population forecasts performed for that have extensive population coverage at least 4 years longitudinal data modelling entering exiting flows registry cohorts. For...
Patients with bronchiectasis have frequent exacerbations that are thought to be related neutrophilic inflammation. The activity and quantity of neutrophil serine proteases, including elastase, increased in the sputum patients at baseline increase further during exacerbations. Brensocatib (INS1007) is an oral reversible inhibitor dipeptidyl peptidase 1 (DPP-1), enzyme responsible for activation proteases.In a phase 2, randomized, double-blind, placebo-controlled trial, we randomly assigned,...
Lower-respiratory-tract infection is one of the most common acute illnesses managed in primary care. Few placebo-controlled studies antibiotics have been done, and overall effectiveness (particularly subgroups such as older people) debated. We aimed to compare benefits harms amoxicillin for lower-respiratory-tract with those placebo both patients aged 60 years or older.Patients than 18 infections (cough ≤28 days' duration) whom pneumonia was not suspected were randomly assigned (1:1) either...
Severe coronavirus disease 2019 (COVID-19) is characterized by an increased risk of thromboembolic events, with evidence microthrombosis in the lungs deceased patients.To investigate mechanism COVID-19 progression.We assessed von Willebrand factor (VWF) antigen (VWF:Ag), VWF ristocetin-cofactor (VWF:RCo), multimers, propeptide (VWFpp), and ADAMTS13 activity a cross-sectional study 50 patients stratified according to their admission three different intensity care units: low (requiring...
Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no approved therapies and few large-scale, representative epidemiological studies. The EMBARC (European Multicentre Audit Research Collaboration) registry a prospective, pan-European observational study patients with bronchiectasis. inclusion criterion primary clinical diagnosis bronchiectasis consisting of: 1) history consistent bronchiectasis; 2) computed tomography demonstrating Core exclusion criteria...
The correct management of immunocompromised patients with pneumonia is debated. We evaluated the prevalence, risk factors, and characteristics coming from community pneumonia.We conducted a secondary analysis an international, multicenter study enrolling adult hospitalized in 222 hospitals 54 countries worldwide. Risk factors for immunocompromise included AIDS, aplastic anemia, asplenia, hematological cancer, chemotherapy, neutropenia, biological drug use, lung transplantation, chronic...